Format
Sort by
Items per page

Send to

Choose Destination

Best matches for Ahlén G[au]:

Search results

Items: 35

1.

Editorial: HBV-the naked truth?

Pasetto A, Ahlén G, Sällberg M.

Aliment Pharmacol Ther. 2019 Oct;50(8):963-964. doi: 10.1111/apt.15428. No abstract available.

2.

Clinical-Grade Oncolytic Adenovirus Purification Using Polysorbate 20 as an Alternative for Cell Lysis.

Moleirinho MG, Rosa S, Carrondo MJT, Silva RJS, Hagner-McWhirter Å, Ahlén G, Lundgren M, Alves PM, Peixoto C.

Curr Gene Ther. 2018;18(6):366-374. doi: 10.2174/1566523218666181109141257.

3.

Immune-mediated effects targeting hepatitis C virus in a syngeneic replicon cell transplantation mouse model.

Levander S, Holmström F, Frelin L, Ahlén G, Rupp D, Long G, Bartenschlager R, Sällberg M.

Gut. 2018 Aug;67(8):1525-1535. doi: 10.1136/gutjnl-2016-313579. Epub 2017 Jun 23.

4.

Functional differences in hepatitis C virus nonstructural (NS) 3/4A- and 5A-specific T cell responses.

Holmström F, Chen M, Balasiddaiah A, Sällberg M, Ahlén G, Frelin L.

Sci Rep. 2016 May 4;6:24991. doi: 10.1038/srep24991.

5.

A non-human hepadnaviral adjuvant for hepatitis C virus-based genetic vaccines.

Levander S, Sällberg M, Ahlén G, Frelin L.

Vaccine. 2016 May 27;34(25):2821-33. doi: 10.1016/j.vaccine.2016.04.030. Epub 2016 Apr 22.

6.

Methods to Evaluate Novel Hepatitis C Virus Vaccines.

Ahlén G, Frelin L.

Methods Mol Biol. 2016;1403:221-44. doi: 10.1007/978-1-4939-3387-7_11.

PMID:
27076133
7.

A targeted controlled force injection of genetic material in vivo.

Ahlén G, Frelin L, Holmström F, Smetham G, Augustyn S, Sällberg M.

Mol Ther Methods Clin Dev. 2016 Mar 30;5:16016. doi: 10.1038/mtm.2016.16. eCollection 2016.

8.

Electroporation for therapeutic DNA vaccination in patients.

Sällberg M, Frelin L, Ahlén G, Sällberg-Chen M.

Med Microbiol Immunol. 2015 Feb;204(1):131-5. doi: 10.1007/s00430-014-0384-8. Epub 2014 Dec 23. Review.

PMID:
25535102
9.

Functional aspects of intrahepatic hepatitis B virus-specific T cells induced by therapeutic DNA vaccination.

Brass A, Frelin L, Milich DR, Sällberg M, Ahlén G.

Mol Ther. 2015 Mar;23(3):578-90. doi: 10.1038/mt.2014.233. Epub 2014 Dec 10.

10.

Long-term functional duration of immune responses to HCV NS3/4A induced by DNA vaccination.

Ahlén G, Holmström F, Gibbs A, Alheim M, Frelin L.

Gene Ther. 2014 Aug;21(8):739-50. doi: 10.1038/gt.2014.48. Epub 2014 May 29.

11.

Cleavage of the T cell protein tyrosine phosphatase by the hepatitis C virus nonstructural 3/4A protease induces a Th1 to Th2 shift reversible by ribavirin therapy.

Brenndörfer ED, Brass A, Karthe J, Ahlén G, Bode JG, Sällberg M.

J Immunol. 2014 Feb 15;192(4):1671-80. doi: 10.4049/jimmunol.1301077. Epub 2014 Jan 17.

12.

Containing "The Great Houdini" of viruses: combining direct acting antivirals with the host immune response for the treatment of chronic hepatitis C.

Ahlén G, Frelin L, Brenndörfer ED, Brass A, Weiland O, Chen M, Sällberg M.

Drug Resist Updat. 2013 Jul-Nov;16(3-5):60-7. doi: 10.1016/j.drup.2013.06.001. Epub 2013 Aug 2. Review.

13.

A heterologous prime/boost vaccination strategy enhances the immunogenicity of therapeutic vaccines for hepatitis C virus.

Fournillier A, Frelin L, Jacquier E, Ahlén G, Brass A, Gerossier E, Holmström F, Broderick KE, Sardesai NY, Bonnefoy JY, Inchauspé G, Sällberg M.

J Infect Dis. 2013 Sep;208(6):1008-19. doi: 10.1093/infdis/jit267. Epub 2013 Jun 17.

14.

Therapeutic DNA vaccination using in vivo electroporation followed by standard of care therapy in patients with genotype 1 chronic hepatitis C.

Weiland O, Ahlén G, Diepolder H, Jung MC, Levander S, Fons M, Mathiesen I, Sardesai NY, Vahlne A, Frelin L, Sällberg M.

Mol Ther. 2013 Sep;21(9):1796-805. doi: 10.1038/mt.2013.119. Epub 2013 Jun 11.

15.

Identification of galactose-α-1,3-galactose in the gastrointestinal tract of the tick Ixodes ricinus; possible relationship with red meat allergy.

Hamsten C, Starkhammar M, Tran TA, Johansson M, Bengtsson U, Ahlén G, Sällberg M, Grönlund H, van Hage M.

Allergy. 2013 Apr;68(4):549-52. doi: 10.1111/all.12128. Epub 2013 Feb 18.

PMID:
23414348
16.

A synthetic codon-optimized hepatitis C virus nonstructural 5A DNA vaccine primes polyfunctional CD8+ T cell responses in wild-type and NS5A-transgenic mice.

Holmström F, Pasetto A, Nähr V, Brass A, Kriegs M, Hildt E, Broderick KE, Chen M, Ahlén G, Frelin L.

J Immunol. 2013 Feb 1;190(3):1113-24. doi: 10.4049/jimmunol.1201497. Epub 2013 Jan 2.

17.

The physician's self-evaluation of the consultation and patient outcome: a longitudinal study.

Ahlén GC, Gunnarsson RK.

Scand J Prim Health Care. 2013 Mar;31(1):26-30. doi: 10.3109/02813432.2012.751692. Epub 2013 Jan 3.

18.

Methods for monitoring gene gun-induced HBV- and HCV-specific immune responses in mouse models.

Ahlén G, Sällberg M, Frelin L.

Methods Mol Biol. 2013;940:239-67. doi: 10.1007/978-1-62703-110-3_20.

PMID:
23104348
19.

Mannosylated mucin-type immunoglobulin fusion proteins enhance antigen-specific antibody and T lymphocyte responses.

Ahlén G, Strindelius L, Johansson T, Nilsson A, Chatzissavidou N, Sjöblom M, Rova U, Holgersson J.

PLoS One. 2012;7(10):e46959. doi: 10.1371/journal.pone.0046959. Epub 2012 Oct 12.

20.

TCR-redirected human T cells inhibit hepatitis C virus replication: hepatotoxic potential is linked to antigen specificity and functional avidity.

Pasetto A, Frelin L, Aleman S, Holmström F, Brass A, Ahlén G, Brenndörfer ED, Lohmann V, Bartenschlager R, Sällberg M, Bertoletti A, Chen M.

J Immunol. 2012 Nov 1;189(9):4510-9. doi: 10.4049/jimmunol.1201613. Epub 2012 Sep 28.

21.

Limited effect on NS3-NS4A protein cleavage after alanine substitutions within the immunodominant HLA-A2-restricted epitope of the hepatitis C virus genotype 3a non-structural 3/4A protease.

Ahlén G, Chen A, Roe B, Falkeborn T, Frelin L, Hall WW, Sällberg M, Söderholm J.

J Gen Virol. 2012 Aug;93(Pt 8):1680-6. doi: 10.1099/vir.0.043745-0. Epub 2012 May 16.

PMID:
22592266
22.

A bi-functional hepatitis B virus core antigen (HBcAg) chimera activates HBcAg-specific T cells and preS1-specific antibodies.

Malik IR, Chen A, Brass A, Ahlén G, Rahman M, Sällberg M, Qureshi JA, Frelin L.

Scand J Infect Dis. 2012 Jan;44(1):55-9. doi: 10.3109/00365548.2011.608711. Epub 2011 Sep 21.

PMID:
21933033
23.

Heterologous T cells can help restore function in dysfunctional hepatitis C virus nonstructural 3/4A-specific T cells during therapeutic vaccination.

Chen A, Ahlén G, Brenndörfer ED, Brass A, Holmström F, Chen M, Söderholm J, Milich DR, Frelin L, Sällberg M.

J Immunol. 2011 May 1;186(9):5107-18. doi: 10.4049/jimmunol.1001790. Epub 2011 Mar 23.

24.

Electroporation: a promising method for the nonviral delivery of DNA vaccines in humans?

Frelin L, Brass A, Ahlén G, Brenndörfer ED, Chen M, Sällberg M.

Drug News Perspect. 2010 Dec;23(10):647-53. doi: 10.1358/dnp.2010.23.10.1513492. Review.

PMID:
21180650
25.

Anti-tumor necrosis factor α treatment promotes apoptosis and prevents liver regeneration in a transgenic mouse model of chronic hepatitis C.

Brenndörfer ED, Weiland M, Frelin L, Derk E, Ahlén G, Jiao J, Bode JG, Sällberg M.

Hepatology. 2010 Nov;52(5):1553-63. doi: 10.1002/hep.23870.

PMID:
20886569
26.

Improving on the ability of endogenous hepatitis B core antigen to prime cytotoxic T lymphocytes.

Nyström J, Chen A, Frelin L, Ahlén G, Koh S, Brass A, Peterson DL, Fons M, Milich DR, Hultgren C, Sällberg M.

J Infect Dis. 2010 Jun 15;201(12):1867-79. doi: 10.1086/652808.

PMID:
20446851
27.

The hepatitis C virus non-structural NS5A protein impairs both the innate and adaptive hepatic immune response in vivo.

Kriegs M, Bürckstümmer T, Himmelsbach K, Bruns M, Frelin L, Ahlén G, Sällberg M, Hildt E.

J Biol Chem. 2009 Oct 9;284(41):28343-51. doi: 10.1074/jbc.M109.038877. Epub 2009 Aug 12.

28.

Cleavage of the IPS-1/Cardif/MAVS/VISA does not inhibit T cell-mediated elimination of hepatitis C virus non-structural 3/4A-expressing hepatocytes.

Ahlén G, Derk E, Weiland M, Jiao J, Rahbin N, Aleman S, Peterson DL, Pokrovskaja K, Grandér D, Frelin L, Sällberg M.

Gut. 2009 Apr;58(4):560-9. doi: 10.1136/gut.2007.147264. Epub 2008 Aug 8.

29.

In vivo electroporation enhances the immunogenicity of hepatitis C virus nonstructural 3/4A DNA by increased local DNA uptake, protein expression, inflammation, and infiltration of CD3+ T cells.

Ahlén G, Söderholm J, Tjelle T, Kjeken R, Frelin L, Höglund U, Blomberg P, Fons M, Mathiesen I, Sällberg M.

J Immunol. 2007 Oct 1;179(7):4741-53.

30.

Physician patient questionnaire to assess physician patient agreement at the consultation.

Ahlén G, Mattsson B, Gunnarsson R.

Fam Pract. 2007 Oct;24(5):498-503. Epub 2007 Jul 26.

PMID:
17656632
31.

The hepatitis C virus and immune evasion: non-structural 3/4A transgenic mice are resistant to lethal tumour necrosis factor alpha mediated liver disease.

Frelin L, Brenndörfer ED, Ahlén G, Weiland M, Hultgren C, Alheim M, Glaumann H, Rozell B, Milich DR, Bode JG, Sällberg M.

Gut. 2006 Oct;55(10):1475-83. Epub 2006 Mar 9.

32.

In vivo clearance of hepatitis C virus nonstructural 3/4A-expressing hepatocytes by DNA vaccine-primed cytotoxic T lymphocytes.

Ahlen G, Nystrom J, Pult I, Frelin L, Hultgren C, Sallberg M.

J Infect Dis. 2005 Dec 15;192(12):2112-6. Epub 2005 Nov 4.

PMID:
16288375
33.

Relation between viral fitness and immune escape within the hepatitis C virus protease.

Söderholm J, Ahlén G, Kaul A, Frelin L, Alheim M, Barnfield C, Liljeström P, Weiland O, Milich DR, Bartenschlager R, Sällberg M.

Gut. 2006 Feb;55(2):266-74. Epub 2005 Aug 16.

34.

Codon optimization and mRNA amplification effectively enhances the immunogenicity of the hepatitis C virus nonstructural 3/4A gene.

Frelin L, Ahlén G, Alheim M, Weiland O, Barnfield C, Liljeström P, Sällberg M.

Gene Ther. 2004 Mar;11(6):522-33.

PMID:
14999224
35.

QUANTITATIVE GAS CHROMATOGRAPHY OF VITAMIN D2.

VESSMAN J, AHLEN G.

Acta Pharm Suec. 1964 Dec;1:209-18. No abstract available.

PMID:
14251864

Supplemental Content

Support Center